Showing results (491-500 of 3,788) with videos related to
Sort By:
Pageof 379
Oncoimmunology|November 20, 2013
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytesZachary A Cooper, Dennie T Frederick, Vikram R Juneja, et al.Oncoimmunology|December 12, 2013
Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells: Killing two birds with one stoneChiara Riganti, Massimo MassaiaOncoimmunology|December 12, 2013
Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4+ and CD8+ T cellsYusuke Tomita, Yasuharu NishimuraOncoimmunology|December 12, 2013
Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironmentMichael H Kershaw, Christel Devaud, Liza B John, et al.Oncoimmunology|December 20, 2013
APLP2 regulates the expression of MHC class I molecules on irradiated Ewing's sarcoma cellsHaley L Peters, Ying Yan, Joyce C SolheimOncoimmunology|December 20, 2013
Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cellsFrédérique Végran, Romain BoidotOncoimmunology|December 19, 2013
HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastomaMadhu Gowda, Kyle K Payne, Kamar Godder, et al.Oncoimmunology|December 10, 2013
Cancer-associated fibroblasts and macrophages: Friendly conspirators for malignancyPaola ChiarugiOncoimmunology|December 10, 2013
Radiation-induced tumor dormancy reflects an equilibrium between the proliferation and T lymphocyte-mediated death of malignant cellsHua Liang, Liufu Deng, Byron Burnette, et al.Oncoimmunology|August 17, 2017
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphomaJulie S Nielsen, Andrew R Chang, Darin A Wick, et al.Pageof 379